• Je něco špatně v tomto záznamu ?

Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child

K. Mitrova, M. Kostrejova, K. Zdychyncova, M. Lukas, D. Duricova

. 2025 ; 19 (4) : . [pub] 20250404

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016171

BACKGROUND AND AIMS: Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). Current guidelines recommend avoiding their use during pregnancy due to safety concerns, as well as during breastfeeding due to the potential excretion into breast milk. METHODS: This case report describes the impact of in utero exposure to tofacitinib during pregnancy and subsequent exposure via breastfeeding on the immune development of the exposed infant. RESULTS: A 37-year-old woman with UC, who was being treated with tofacitinib and vedolizumab, became pregnant and continued both medications, with the tofacitinib dosage reduced from 10 to 5 mg BID at gestational week 28. The infant was born healthy, with normal growth and development, and received all scheduled non-live vaccinations. At 15 months, immune parameters-including response to vaccination-were evaluated. The results showed normal immunoglobulin levels and an adequate serologic response to vaccination, with no signs of immune dysfunction. CONCLUSIONS: This case suggests that prolonged prenatal and postnatal exposure to tofacitinib may not adversely affect infant immune development. However, caution is advised due to the limited number of documented cases. Further research is needed to fully understand the long-term implications of JAK inhibitor exposure during pregnancy and breastfeeding.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016171
003      
CZ-PrNML
005      
20250731091548.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjaf049 $2 doi
035    __
$a (PubMed)40127036
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mitrova, Katarina $u Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $1 https://orcid.org/0000000218363745
245    10
$a Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child / $c K. Mitrova, M. Kostrejova, K. Zdychyncova, M. Lukas, D. Duricova
520    9_
$a BACKGROUND AND AIMS: Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). Current guidelines recommend avoiding their use during pregnancy due to safety concerns, as well as during breastfeeding due to the potential excretion into breast milk. METHODS: This case report describes the impact of in utero exposure to tofacitinib during pregnancy and subsequent exposure via breastfeeding on the immune development of the exposed infant. RESULTS: A 37-year-old woman with UC, who was being treated with tofacitinib and vedolizumab, became pregnant and continued both medications, with the tofacitinib dosage reduced from 10 to 5 mg BID at gestational week 28. The infant was born healthy, with normal growth and development, and received all scheduled non-live vaccinations. At 15 months, immune parameters-including response to vaccination-were evaluated. The results showed normal immunoglobulin levels and an adequate serologic response to vaccination, with no signs of immune dysfunction. CONCLUSIONS: This case suggests that prolonged prenatal and postnatal exposure to tofacitinib may not adversely affect infant immune development. However, caution is advised due to the limited number of documented cases. Further research is needed to fully understand the long-term implications of JAK inhibitor exposure during pregnancy and breastfeeding.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a těhotenství $7 D011247
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a kojení $7 D001942
650    12
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    12
$a inhibitory Janus kinas $x škodlivé účinky $7 D000075242
650    12
$a piperidiny $x škodlivé účinky $x terapeutické užití $7 D010880
650    _2
$a komplikace těhotenství $x farmakoterapie $7 D011248
650    12
$a zpožděný efekt prenatální expozice $x imunologie $x chemicky indukované $7 D011297
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $7 D047428
650    12
$a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a pyrroly $x škodlivé účinky $x terapeutické užití $7 D011758
655    _2
$a časopisecké články $7 D016428
655    _2
$a kazuistiky $7 D002363
700    1_
$a Kostrejova, Marta $u Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic
700    1_
$a Zdychyncova, Kristyna $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $1 https://orcid.org/0000000214633840 $7 jn19990202012
700    1_
$a Duricova, Dana $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $u Department of Pharmacology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u Hepatogastroenterology Clinic, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00166945 $t Journal of Crohn's and colitis $x 1876-4479 $g Roč. 19, č. 4 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40127036 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091543 $b ABA008
999    __
$a ok $b bmc $g 2366773 $s 1253296
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 19 $c 4 $e 20250404 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace